miRNA-27a与TOP2A蛋白在乳腺癌化疗中的表达水平及效能评估  

Expression Levels and Efficacy Evaluation of miRNA-27a and TOP2A Protein in Breast Cancer Chemotherapy

作　　者：焦德[1] 陈冰[1] 齐亚宾 张荣君 刘保国[1] JIAO De;CHEN Bing;QI Yabin;ZHANG Rongjun;LIU Baoguo(Department of Breast and Thyroid Surgery,Liaocheng People’s Hospital,Liaocheng Shandong 252000,China)

机构地区：[1]聊城市人民医院乳甲外科,山东聊城252000

出　　处：《中国医疗设备》2024年第7期136-141,146,共7页China Medical Devices

基　　金：国家自然科学基金资助项目(81473268)。

摘　　要：目的探析微核糖核酸-27a(microRNA-27a,miRNA-27a)与DNA拓扑异构酶Ⅱα(TopoisomeraseⅡ-Alpha,TOP2A)蛋白在乳腺癌化疗中的表达水平及预测效能。方法回顾性分析2020年1月至2022年1月聊城市人民医院乳甲外科收治的47例乳腺癌患者的病案资料,均接受化疗治疗。用实时荧光定量PCR法进行血浆miRNA-27a表达水平的检测,用免疫组织化学法进行TOP2A蛋白表达情况的检测。比较乳腺癌患者化疗前后的miRNA-27a、TOP2A蛋白表达水平差异,采用Logistic回归分析法探析miRNA-27a、TOP2A蛋白与乳腺癌化疗预后不良的关系,绘制受试者工作特征(Receiver Operating Characteristic,ROC)曲线分析miRNA-27a、TOP2A蛋白在乳腺癌化疗疗效预测中的应用价值。结果47例患者开始化疗后第4个月的miRNA-27a、TOP2A蛋白检测值显著低于化疗前(入院时)(P<0.05)。开始化疗后第4个月,预后良好35例(74.47%),预后不良12例(25.53%),预后良好组的miRNA-27a、TOP2A蛋白检测值低于预后不良组。Logistic分析结果显示,miRNA-27a、TOP2A蛋白高表达是乳腺癌化疗预后不良的危险因素(P<0.05)。ROC曲线结果显示,miRNA-27a、TOP2A蛋白联合预测乳腺癌化疗预后不良的曲线下面积(0.875,95%CI:0.798~0.952)最大,敏感度、特异性分别为91.67%、94.29%(P<0.05)。结论miRNA-27a、TOP2A蛋白在乳腺癌化疗预后不良中呈高表达,若乳腺癌化疗患者miRNA-27a、TOP2A蛋白表达水平显著上升,侧面说明患者病情可能有恶化风险,化疗疗效有限。Objective To analyze the expression levels and predictive efficacy of microRNA-27a(miRNA-27a)and DNA topoisomeraseⅡ-Alpha(TOP2A)protein in breast cancer chemotherapy.Methods The medical records of 47 patients with breast cancer admitted to the Breast and Thyroid Surgery Department of Liaocheng People’s Hospital from January 2020 to January 2022 were retrospectively analyzed,and all patients received chemotherapy treatment.The expression level of miRNA-27a in plasma was detected by quantitative real-time PCR method,and the expression of TOP2A protein was detected by immunohistochemistry method.Differences in the expression levels of miRNA-27a and TOP2A protein before and after chemotherapy were compared,and the relationship between miRNA-27a and TOP2A protein and poor prognosis of breast cancer chemotherapy was analyzed by Logistic regression analysis.Receiver operating characteristic(ROC)curve was drawn to analyze the application value of miRNA-27a and TOP2A proteins in the prediction of chemotherapy efficacy for breast cancer.Results The levels of miRNA-27a and TOP2A protein detected in 47 patients at the fourth month after starting chemotherapy were significantly lower than before chemotherapy(upon admission)(P<0.05).At the fourth month after starting chemotherapy,35 cases(74.47%)had a good prognosis,while 12 cases(25.53%)had a poor prognosis,and the detection values of miRNA-27a and TOP2A protein in the good prognosis group were lower than those in the poor prognosis group.Logistic regression analysis showed that high expression of miRNA-27a and TOP2A protein was a risk factor for poor prognosis in breast cancer chemotherapy(P<0.05).The ROC curve showed that the combination of miRNA-27a and TOP2A protein had the largest area under curve(0.875,95%CI:0.798-0.952)in predicting poor prognosis of breast cancer chemotherapy,with sensitivity and specificity of 91.67%and 94.29%,respectively(P<0.05).Conclusion miRNA-27a and TOP2A proteins are highly expressed in patients with poor prognosis of breast cancer chemoth

关 键 词：乳腺癌 化疗 微核糖核酸 TOP2A蛋白 人类表皮生长因子受体2 

分 类 号：R737.9[医药卫生—肿瘤]